Key result
SGLT2 inhibitors improve heart failure outcomes through diverse mechanisms despite absent cardiac SGLT2 expression.
Why the study?
SGLT2 inhibitors improve heart failure outcomes despite no evidence of cardiac SGLT2 expression, prompting investigation into their mechanisms of efficacy.
This review outlines the current understanding of the proposed mechanistic pathways underlying the clinical benefits of SGLT2 inhibitors in heart failure.
Heart failure (HF) is a leading cause of hospitalizations and deaths worldwide. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve HF outcomes despite no evidence of cardiac SGLT2 expression. This forum highlights some proposed mechanisms of SGLT2i efficacy, limitations of these studies, and potential future directions.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2026) studied this question. SGLT2 inhibitors improve heart failure outcomes through various proposed mechanisms despite a lack of evidence for direct cardiac SGLT2 expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: